Cullinan Therapeutics, Inc. 8-K

What Happened

• On June 10, 2026 Cullinan Therapeutics (CGEM) filed an 8‑K and issued a press release reporting updated interim clinical data. As of May 20, 2026, multi‑dose data from the Phase 1 OUTRACE RA trial for CLN‑978 show robust responses in two heavily pretreated, poly‑refractory rheumatoid arthritis (RA) patients, including one patient achieving DAS28‑ESR remission (baseline 4.0 → 2.2 at week 4, maintained at week 8) with rapid reduction in RA autoantibodies. As of May 20, 2026, early multi‑dose safety data in three SLE patients (OUTRACE SLE) are consistent with the favorable profile seen in RA, and observations in patients with lupus nephritis showed rapid improvement in proteinuria. The company expects a Phase 2a expansion in lupus nephritis to begin in early 2027 and plans additional multi‑dose RA data in Q3 2026 and SLE data in Q4 2026.
• Also on June 10, Cullinan reported initial results from a Phase 1b/2a trial of velinotamig run by partner Chongqing Genrix in China. As of May 15, 2026, the first two refractory SLE patients who received four IV doses (3 µg/kg day 1, then 10 µg/kg ×3) had rapid, marked falls in SLEDAI‑2K (baseline 16 and 14 → week‑8 scores 0 and 2) and proteinuria; both achieved complete renal response. Velinotamig was well tolerated in these patients with no cytokine release syndrome (CRS) or immune effector cell‑associated neurotoxicity syndrome (ICANS) observed. Additional Genrix multi‑dose SLE data are expected in Q4 2026, and Cullinan plans a Phase 1/2a trial in autoimmune cytopenias in Q1 2027.

Key Details

• Filing date: June 10, 2026 (Form 8‑K).
• CLN‑978 OUTRACE RA: one patient achieved DAS28‑ESR remission (4.0 → 2.2 by week 4, maintained at week 8).
• CLN‑978 OUTRACE SLE: multi‑dose safety in first three patients consistent with prior RA cohort; lupus nephritis improvement supports Phase 2a expansion expected early 2027.
• Velinotamig (Genrix trial, China): two patients completed 4 IV doses (3 µg/kg then 10 µg/kg ×3); SLEDAI‑2K fell from 16 and 14 to 0 and 2 at week 8; both achieved complete renal response; no CRS or ICANS observed.
• Upcoming data timing: CLN‑978 RA data in Q3 2026, CLN‑978 SLE and additional velinotamig data in Q4 2026.

Why It Matters

• These are early, interim but clinically meaningful signals in small, treatment‑refractory patient groups—positive efficacy and tolerability could de‑risk Cullinan’s CLN‑978 and velinotamig programs if reproduced in larger trials.
• The reported timing for additional readouts (Q3/Q4 2026) and planned Phase 2a and Phase 1/2a starts (early 2027) create near‑term clinical milestones that investors often view as catalysts.
• Caveat: the data are interim and from very small patient numbers; Cullinan’s filing includes standard forward‑looking disclaimers that outcomes may change as trials continue and additional data are collected.